Parasite Targets Research Articles

Disentangling the effects of intermittent faecal shedding and imperfect test sensitivity on the microscopy-based detection of gut parasites in stool samples.

Gut-parasite transmission often involves faecal shedding, and detecting parasites in stool samples remains the cornerstone of diagnosis. However, not all samples drawn from infected hosts contain parasites (because of intermittent shedding), and no test can detect the target parasites in 100% of parasite-bearing samples (because of imperfect sensitivity). Disentangling the effects of intermittent shedding and imperfect sensitivity on pathogen detection would help us better understand transmission dynamics, disease epidemiology, and diagnostic-test performance. Using paediatric Giardia infections as a case-study, here we illustrate a hierarchical-modelling approach to separately estimating the probabilities of host-level infection (Ψ); stool-sample-level shedding, given infection (θ); and test-level detection, given infection and shedding (p). We collected 1-3 stool samples, in consecutive weeks, from 276 children. Samples (413 overall) were independently examined, via standard sedimentation/optical microscopy, by a senior parasitologist and a junior, trained student (826 tests overall). Using replicate test results and multilevel hierarchical models, we estimated per-sample Giardia shedding probability at [Formula: see text] and observer-specific test sensitivities at [Formula: see text] and [Formula: see text]. Gender-specific infection-frequency estimates were [Formula: see text] and [Formula: see text]. Had we used a (hypothetical) Perfect Test with 100% narrow-sense sensitivity (pPT = 1.0), the average probability of detecting Giardia in a sample drawn from an infected child (Ψ = 1.0) would have been Pr(d|i,PT) = Ψ×θ×pPT≈1.0×0.44×1.0≈0.44. Because no test can be >100% sensitive, Pr(d|i) (which measures clinical sensitivity) can only be brought above ~ 0.44 by tinkering with the availability of Giardia in stool samples (i.e., θ); for example, drawing-and-pooling 3 replicate samples would yield [Formula: see text]. By allowing separate estimation (and modelling) of pathogen-shedding probabilities, the approach we illustrate provides a means to study pathogen transmission cycles and dynamics in unprecedented detail. Separate estimation (and modelling) of true test sensitivity, moreover, may cast new light on the performance of diagnostic tests and procedures, whether novel or routine-practice.

Synthesis of 1,4 Naphthoquinone Derivatives and Their In-silico Evaluations

In this study, we explored the arylation of 1,4-naphthoquinone with the help of Palladium acetate (Pd oAC). The synthesized compounds was characterized by using Proton NMR,and HR-Mass spectrometry and were subjected to molecular at this strategic position to evaluate its biological efficacy against anti-inflammation the parasitic target of the protein receptor 1W3R.The docking studies using the 1W3R protein structure to assess their binding affinities and interactions, comparing them to the clinically used drug, metronidazole. Results from the docking studies showed that the arylated 1,4-naphthoquinone derivatives exhibited stronger binding interactions at the active site of 1W3R than metronidazole, suggesting enhanced inhibition potential. Additionally, ADMET (absorption, distribution, metabolism, excretion, and toxicity) profiles were evaluated to assess the pharmacokinetics and safety of the compounds. The arylated derivatives displayed favorable ADMET properties, including good oral bioavailability and low toxicity, which further supports their potential as therapeutic agents. These findings suggest that second-position arylated 1,4-naphthoquinones may serve as promising leads for potential advantages over metronidazole. Further experimental validation and optimization of these compounds are recommended to fully harness their therapeutic potential.This research highlights the importance of scaffold functionalization in drug discovery and the potential of 1,4-naphthoquinone derivatives in developing new targeted Anti-inflammation therapies.

Investigation of the Effects of Lycorine and Galanthamine Extracted from Galanthus elwesii on Viral and Parasitic Targets: An In-Silico Analysis and DFT Study

: In this study, Density Functional Theory (DFT), ADME property analysis, and molecular docking simulations were employed to evaluate the electronic structure, antiviral potential, and antiparasitic effects of lycorine and galanthamine, two alkaloids extracted from Galanthus elwesii. DFT calculations revealed that lycorine has a lower e_gap compared to galanthamine, suggesting higher reactivity and lower stability, enhancing its potential as a drug candidate. Pharmacokinetic profiling indicated that galanthamine (TPSA: 41.93 Ų, logP: 0.797) has a lower total polar surface area (TPSA) and higher lipophilicity (logP) compared to lycorine (TPSA: 62.16 Ų, logP: -0.268), indicating that galanthamine may possess superior absorption and permeability characteristics. ADME analysis also identified galanthamine as having a lower AMES toxicity score, implying reduced mutagenic risk. A total of nine target proteins, representing viral and parasitic diseases Zika virus, malaria, leishmaniasis, and dengue, were chosen for molecular docking. Molecular docking studies demonstrated that lycorine exhibited superior binding interactions (-8.76 kcal/mol), particularly against Leishmania, and displayed stronger binding affinity across all selected target proteins. Despite galanthamine's lower toxicity profile, lycorine’s enhanced reactivity and stronger binding properties suggest its higher efficacy as a therapeutic candidate based on DFT and molecular docking results, while galanthamine shows potential based on its favourable ADME profile.

Development of non-sedating benzodiazepines with in vivo antischistosomal activity.

The neglected tropical disease schistosomiasis infects over 200 million people worldwide and is treated with just one broad-spectrum antiparasitic drug (praziquantel). Alternative drugs are needed in the event of emerging praziquantel resistance or treatment failure. One promising lead that has shown efficacy in animal models and a human clinical trial is the benzodiazepine meclonazepam, discovered by Roche in the 1970s. Meclonazepam was not brought to market because of dose-limiting sedative side effects. However, the human target of meclonazepam that causes sedation (GABAARs) is not orthologous to the parasite targets that cause worm death. Therefore, we were interested in whether the structure of meclonazepam could be modified to produce antiparasitic benzodiazepines that do not cause host sedation. We synthesized 18 meclonazepam derivatives with modifications at different positions on the benzodiazepine ring system and tested them for in vitro antiparasitic activity. This identified five compounds that progressed to in vivo screening in a murine model, two of which cured parasite infections with comparable potency to meclonazepam. When these two compounds were administered to mice that were run on the rotarod test, both were less sedating than meclonazepam. These findings demonstrate the proof of concept that meclonazepam analogs can be designed with an improved therapeutic index and point to the C3 position of the benzodiazepine ring system as a logical site for further structure-activity exploration to further optimize this chemical series.

Discovery of 8-hydroxy-2-quinoline carbaldehyde derivatives as inhibitors for M1 aminopeptidase of Leishmania donovani

M1 aminopeptidase is a metallopeptidase that plays a vital role in protein catabolism and has been identified as a validated drug target in various parasites; however, our understanding of this enzyme is restricted for leishmanial parasite. The present investigation involved the purification of Leishmania donovani M1 aminopeptidase (LdM1AP) to homogeneity by affinity chromatography. Purified LdM1AP was observed to be enzymatically active and displayed maximal activity in the presence of cobalt ions, whereas secondary structure analysis confirmed the dominance of α-helices. Intrinsic fluorescence and quenching studies of LdM1AP has revealed that tryptophan residues were predominantly concealed within the hydrophobic areas. The synthesized 8-hydroxy-2-quinoline carbaldehyde derivatives were screened, wherein HQ2 and HQ12 were found as potent inhibitors for LdM1AP that compete with the substrate and exhibit pharmacokinetic properties as well as no toxicity for macrophages. Moreover, structural insights of protein and ligand complexes demonstrated that lead compounds mostly interact via hydrophobic contacts into the substrate binding pocket of LdM1AP. Furthermore, lead compounds exhibited a greater affinity for LdM1AP compared to the substrate during in vitro and in silico studies. This report establishes the possibility of quinoline derivatives to target the LdM1AP activity and provide a platform to design the specific antileishmanial drugs.

To quest new targets of Plasmodium parasite and their potential inhibitors to combat antimalarial drug resistance.

Malaria remains a global health challenge with significant mortality and morbidity annually, with resistant parasite strains complicating treatment efforts. There is an acute need for novel antimalarial drugs that can put a stop to the future public health crisis caused by the multi-drug resistance strains of the Plasmodium parasite. However, the discovery of these new components is very challenging in the context of the generation of multi-drug resistance properties of malaria. The novel drugs also need to have several properties involving enhanced therapeutic prospects, successful treatment capabilities, and novel mechanisms of action that will forestall the resistance. To successfully achieve this aim researchers are trying to focus on exploring promising malaria targets. Various approaches have been made for the development of drugs for malaria including the remodelling of existing drugs and the development of novel inhibitors which acts on new targets. Advancement in the study provides more information on the biology of parasites and the new targets which help in the development of novel drugs. The present review focuses on the study of novel targets of malaria parasites and subsequent inhibitors of those particular targets. Some of these targets include malarial protease, various transporter proteins, enzymes involved in the synthesis of DNA, and nucleic acids like dihydroorotate dehydrogenase, dihydrofolate reductase, apicoplast and dihydropteroate synthase. Other potential targets are also included in this review such as isoprenoid biosynthesis, farnesyl transferase of parasite, P. falciparum translational elongation factor 2, and phosphatidyl inositol 4 kinase. These promising targets have also been summed up along with their corresponding inhibitors for combating multi-drug resistance malaria.

Insights into the Mechanism of Catalytic Activity of Plasmodium Parasite Malate-Quinone Oxidoreductase.

Plasmodium malate-quinone oxidoreductase (MQO) is a membrane flavoprotein catalyzing the oxidation of malate to oxaloacetate and the reduction of quinone to quinol. Recently, using a yeast expression system, we demonstrated that MQO, expressed in place of mitochondrial malate dehydrogenase (MDH), contributes to the TCA cycle and the electron transport chain in mitochondria, making MQO attractive as a promising drug target in Plasmodium malaria parasites, which lack mitochondrial MDH. However, there is little information on the structure of MQO and its catalytic mechanism, information that will be required to develop novel drugs. Here, we investigated the catalytic site of P. falciparum MQO (PfMQO) using our yeast expression system. We generated a model structure for PfMQO with the AI tool AlphaFold and used protein footprinting by acetylation with acetic anhydride to analyze the surface topology of the model, confirming the computational prediction to be reasonably accurate. Moreover, a putative catalytic site, which includes a possible flavin-binding site, was identified by this combination of protein footprinting and structural prediction model. This active site was analyzed by site-directed mutagenesis. By measuring enzyme activity and protein expression levels in the PfMQO mutants, we showed that several residues at the active site are essential for enzyme function. In addition, a single substitution mutation near the catalytic site resulted in enhanced sensitivity to ferulenol, an inhibitor of PfMQO that competes with malate for binding to the enzyme. This strongly supports the notion that the substrate binds to the proposed catalytic site. Then, the location of the catalytic site was demonstrated by structural comparison with a homologous enzyme. Finally, we used our results to propose a mechanism for the catalytic activity of MQO by reference to the mechanism of action of structurally or functionally homologous enzymes.

Copaifera spp. oleoresins and two isolated compounds (ent-kaurenoic and ent-polyalthic acid) inhibit Toxoplasma gondii growth in vitro

Toxoplasmosis affects about one-third of the world's population. The disease treatment methods pose several side effects and do not efficiently eliminate the parasite, making the search for new therapeutic approaches necessary. We aimed to assess the anti-Toxoplasma gondii activity of four Copaifera oleoresins (ORs) and two isolated diterpene acids, named ent-kaurenoic and ent-polyalthic acid. We used HeLa cells as an experimental model of toxoplasmosis. Uninfected and infected HeLa cells were submitted to the treatments, and the parasite intracellular proliferation, cytokine levels and ROS production were measured. Also, tachyzoites were pre-treated and the parasite invasion was determined. Finally, an in silico analysis was performed to identify potential parasite targets. Our data show that the non-cytotoxic concentrations of ORs and diterpene acids controlled the invasion and proliferation of T. gondii in HeLa cells, thus highlighting the possible direct action on parasites. In addition, some compounds tested controlled parasite proliferation in an irreversible manner. An additional and non-exclusive mechanism of action involves the modulation of host cell components, by affecting the upregulation of the IL-6. Additionally, molecular docking suggested that ent-polyalthic acid has a high affinity for the active site of the TgCDPK1 protein. Copaifera ORs have great antiparasitic activity against T. gondii, and this effect can be partially explained by the presence of the isolated compounds ent-kaurenoic and ent-polyalthic acid.

Profile of metacaspase gene expression in Plasmodium vivax field isolates from the Brazilian Amazon

BackgroundMetacaspases comprise a family of cysteine proteases implicated in both cell death and cell differentiation of protists that has been considered a potential drug target for protozoan parasites. However, the biology of metacaspases in Plasmodium vivax − the second most prevalent and most widespread human malaria parasite worldwide, whose occurrence of chemoresistance has been reported in many endemic countries, remains largely unexplored. Therefore, the present study aimed to address, for the first time, the expression pattern of metacaspases in P. vivax parasites.Methods and resultsP. vivax blood-stage parasites were obtained from malaria patients in the Brazilian Amazon and the expression of the three putative P. vivax metacaspases (PvMCA1-3) was detected in all isolates by quantitative PCR assay. Of note, the expression levels of each PvMCA varied noticeably across isolates, which presented different frequencies of parasite forms, supporting that PvMCAs may be expressed in a stage-specific manner as previously shown in P. falciparum.ConclusionThe detection of metacaspases in P. vivax blood-stage parasites reported herein, allows the inclusion of these proteases as a potential candidate drug target for vivax malaria, while further investigations are still required to evaluate the activity, role and essentiality of metacaspases in P. vivax biology.

Iso-mukaadial acetate and ursolic acid acetate bind to Plasmodium Falciparum heat shock protein 70: towards targeting parasite protein folding pathway.

Plasmodium falciparum is the most lethal malaria parasite. P. falciparum Hsp70 (PfHsp70) is an essential molecular chaperone (facilitates protein folding) and is deemed a prospective antimalarial drug target. The present study investigates the binding capabilities of select plant derivatives, iso-mukaadial acetate (IMA) and ursolic acid acetate (UAA), against P. falciparum using an in silico docking approach. The interaction between the ligands and PfHsp70 was evaluated using plasmon resonance (SPR) analysis. Molecular docking, binding free energy analysis and molecular dynamics simulations were conducted towards understanding the mechanisms by which the compounds bind to PfHsp70. The molecular docking results revealed ligand flexibilities, conformations and positions of key amino acid residues and protein-ligand interactions as crucial factors accounting for selective inhibition of Hsp70. The simulation results also suggest protein-ligand van der Waals forces as the driving force guiding the interaction of these compounds with PfHsp70. Of the two compounds, UAA and IMA bound to PfHsp70 within the micromolar range based on surface plasmon resonance (SPR) based binding assay. Our findings pave way for future rational design of new selective compounds targeting PfHsp70.

Transcriptomics of Besnoitia besnoiti-Infected Fibroblasts Reveals Hallmarks of Early Fibrosis and Cancer Progression.

Endothelial injury, inflammatory infiltrate and fibrosis are the predominant lesions in the testis of bulls with besnoitiosis that may result in sterility. Moreover, fibroblasts, which are key players in fibrosis, are parasite target cells in a Besnoitia besnoiti chronic infection. This study aimed to decipher the molecular basis that underlies a drift toward fibrosis during the disease progression. Transcriptomic analysis was developed at two times post-infection (p.i.), representative of invasion (12 h p.i.) and intracellular proliferation (32 h p.i.), in primary bovine aorta fibroblasts infected with B. besnoiti tachyzoites. Once the enriched host pathways were identified, we studied the expression of selected differentially expressed genes (DEGs) in the scrotal skin of sterile infected bulls. Functional enrichment analyses of DEGs revealed shared hallmarks of cancer and early fibrosis. Biomarkers of inflammation, angiogenesis, cancer, and MAPK signaling stood out at 12 h p.i. At 32 h p.i., again MAPK and cancer pathways were enriched together with the PI3K-AKT pathway related to cell proliferation. Some DEGs were also regulated in the skin samples of naturally infected bulls (PLAUR, TGFβ1, FOSB). We have identified potential biomarkers and host pathways regulated during fibrosis that may hold prognostic significance and could emerge as potential therapeutic targets.

Theileria parasites sequester host eIF5A to escape elimination by host-mediated autophagy

Intracellular pathogens develop elaborate mechanisms to survive within the hostile environments of host cells. Theileria parasites infect bovine leukocytes and cause devastating diseases in cattle in developing countries. Theileria spp. have evolved sophisticated strategies to hijack host leukocytes, inducing proliferative and invasive phenotypes characteristic of cell transformation. Intracellular Theileria parasites secrete proteins into the host cell and recruit host proteins to induce oncogenic signaling for parasite survival. It is unknown how Theileria parasites evade host cell defense mechanisms, such as autophagy, to survive within host cells. Here, we show that Theileria annulata parasites sequester the host eIF5A protein to their surface to escape elimination by autophagic processes. We identified a small-molecule compound that reduces parasite load by inducing autophagic flux in host leukocytes, thereby uncoupling Theileria parasite survival from host cell survival. We took a chemical genetics approach to show that this compound induced host autophagy mechanisms and the formation of autophagic structures via AMPK activation and the release of the host protein eIF5A which is sequestered at the parasite surface. The sequestration of host eIF5A to the parasite surface offers a strategy to escape elimination by autophagic mechanisms. These results show how intracellular pathogens can avoid host defense mechanisms and identify a new anti-Theileria drug that induces autophagy to target parasite removal.

Progress interrogating TRPMPZQ as the target of praziquantel.

The drug praziquantel (PZQ) has served as the long-standing drug therapy for treatment of infections caused by parasitic flatworms. These encompass diseases caused by parasitic blood, lung, and liver flukes, as well as various tapeworm infections. Despite a history of clinical usage spanning over 4 decades, the parasite target of PZQ has long resisted identification. However, a flatworm transient receptor potential ion channel from the melastatin subfamily (TRPMPZQ) was recently identified as a target for PZQ action. Here, recent experimental progress interrogating TRPMPZQ is evaluated, encompassing biochemical, pharmacological, genetic, and comparative phylogenetic data that highlight the properties of this ion channel. Various lines of evidence that support TRPMPZQ being the therapeutic target of PZQ are presented, together with additional priorities for further research into the mechanism of action of this important clinical drug.

TRP drop, TRP drop: a steady patter of anti-schistosomal target illumination

Infections caused by parasitic flatworms impart a significant disease burden. This is well exemplified by the neglected tropical disease schistosomiasis, which afflicts millions of people worldwide. The anti-schistosomal activity of various chemotypes has been known for decades, but the parasite targets of many of these remain undefined. Until recently, this included the current clinical therapy, praziquantel (PZQ). However, the tempo of target discovery has recently gathered pace, with discoveries of schistosome targets for praziquantel (PZQ) and the anthelmintic benzodiazepine, meclonazepam (MCLZ). This steady patter of target illumination has also revealed a pattern in that both PZQ and MCLZ target members of the same ion channel subgroup—transient receptor potential ion channels of the melastatin family (TRPM channels). PZQ activates one member of this family (TRPMPZQ) and MCLZ activates a different channel (TRPMMCLZ). Here, similarities and differences between these two new targets are discussed. These data highlight the need for further study of TRPM channels in parasitic flatworms given their vulnerability to chemotherapeutic attack.

<b>Potency of anti-trematode in inhibiting cathepsin-2L and cathepsin-5L of <i>Fasciola gigantica</i> using homology, docking, and molecular dynamics</b>

<b>Background: </b> Cathepsin-L (FhCL) is a group of enzymes that most flukes express and secreted significantly in parasite-host interactions. Researches are focusing on antigens released by Fasciola gigantica as one of the keys for understanding immunologic pathway in parasite infection and targets for anthelmintics. Efforts to suppress FhCL function through vaccination or therapy using anthelmintic drugs are key factors in controlling field level trematode infections. A molecular docking method can be used to observe the interaction between FhCL and some anthelmintic drugs to better understand the effect of these anthelmintics on FhCL. Furthermore, it is necessary to carry out molecular dynamics method to observe the dynamic pattern of the interaction of the enzyme-ligand when the dynamics simulation is in progress. <b>Aim: </b> This study was carried out to screen six commercial anthelmintic drugs against cathepsin-2L (FhCL-2) and cathepsin 5L (FhCL-5) using in silico and molecular dynamics approach. <b>Methods: </b> The three-dimensional (3D) crystal structure of FhCL-2 and FhCL-5 enzymes were constructed based on the crystal structure of ProCathepsin 1L (pdb id. 2O6X) as a template, while six anthelmintic agents (“SMILES” format) were downloaded from PubChem and converted to 3D format using the MOE Builder tool. The enzyme modelling results were evaluated using the "Ramachandran Plot". <b>Results: </b> Molecular docking results showed that all tested ligands had affinity for FhCL-2 and FhCL-5. The best ∆Gbinding value for FhCL-2 was clorsulon ligand (-15.21 kcal/mol) with pKi of 32.25 µM, which was significantly different compared to other drugs (p<0.05). For FhCL-5, the best ∆Gbinding value was closantel ligand (-14.88 kcal/mol) with pKi of 31.51 µM, significantly different from other drugs tested (p<0.05). The results of the molecular dynamics simulation for the two ligands showed a strong and stable interaction at their respective binding sites. <b>Conclusion: </b> All of the tested anti-trematode ligands had potency as inhibitors for FhCL-2 and FhCL-5 enzymes of F. gigantica, and the best candidate for FhCL-2 was clorsulon, and for FhCL-5 was closantel. This finding is useful as an approach to develop novel drugs from existing drugs as inhibitors for FhCL-2 and FhCL-5 enzymes.

Promising antimalarial hits from phenotypic screens: a review of recently-described multi-stage actives and their modes of action.

Over the last two decades, global malaria cases caused by Plasmodium falciparum have declined due to the implementation of effective treatments and the use of insecticides. However, the COVID-19 pandemic caused major disruption in the timely delivery of medical goods and diverted public health resources, impairing malaria control. The emergence of resistance to all existing frontline antimalarials underpins an urgent need for new antimalarials with novel mechanisms of action. Furthermore, the need to reduce malaria transmission and/or prevent malaria infection has shifted the focus of antimalarial research towards the discovery of compounds that act beyond the symptomatic blood stage and also impact other parasite life cycle stages. Phenotypic screening has been responsible for the majority of new antimalarial lead compounds discovered over the past 10 years. This review describes recently reported novel antimalarial hits that target multiple parasite stages and were discovered by phenotypic screening during the COVID-19 pandemic. Their modes of action and targets in blood stage parasites are also discussed.

The anthelmintic meclonazepam activates a schistosome transient receptor potential channel

Parasitic flatworms cause various clinical and veterinary infections that impart a huge burden worldwide. The most clinically impactful infection is schistosomiasis, a neglected tropical disease caused by parasitic blood flukes. Schistosomiasis is treated with praziquantel (PZQ), an old drug introduced over 40 years ago. New drugs are urgently needed, as while PZQ is broadly effective it suffers from several limitations including poor efficacy against juvenile worms which may prevent it from being completely curative. An old compound that retains efficacy against juvenile worms is the benzodiazepine meclonazepam (MCLZ). However, host side effects caused by benzodiazepines preclude development of MCLZ as a drug, and MCLZ lacks an identified parasite target to catalyze rational drug design for engineering out human host activity. Here, we identify a transient receptor potential ion channel of the melastatin subfamily, named TRPMMCLZ, as a parasite target of MCLZ. MCLZ potently activates Schistosoma mansoni TRPMMCLZ through engagement of a binding pocket within the voltage-sensor like domain of the ion channel to cause worm paralysis, tissue depolarization and surface damage. TRPMMCLZ reproduces all known features of MCLZ action on schistosomes, including a lower activity versus Schistosoma japonicum which is explained by a polymorphism within this VSLD binding pocket. TRPMMCLZ is distinct from the TRP channel targeted by PZQ (TRPMPZQ), with both anthelmintic chemotypes targeting unique parasite TRPM paralogs. This advances TRPMMCLZ as a novel druggable target that could circumvent target-based resistance emerging in response to current mass drug administration campaigns centered around PZQ.

Anthelmintic Efficacy of Butea Frondosa and Albendazole in Gastrointestinal Nematode Infected Goats of District Indore-madhya Pradesh, India

A wide variety of secondary metabolites with intriguing biological functions are produced by plants. The active component of Butea frondosa, palasonin, inhibits the uptake of glucose and depletes the content of glycogen; hence, the mechanism of action of this anthelminthic agent may involve the suppression of energy metabolism. These medications frequently disrupt key parasitic targets, including membrane integrity, microtubules, DNA (intercalation and alkylation), and neural signal transduction. The goal of this study was to determine how well methanolic extracts from Butea frondosa seeds and albendazole worked as anthelmintics against gastrointestinal nematodes. The egg hatch assay (EHA) was used to conduct an in vitro study on several gastrointestinal nematode stages. Using the methods of egg per gram of feces and faecal egg count reduction (FECR) in vivo. Methanolic treatment was given to goats. The extract of Butea frondosa @ 150 mg/kg b.w. on day 0, 3 and 7. Eggs per gram of faeces were recorded as 883.30 ± 94.60, 783.30 ± 70.30, 333.30 ± 98.90, 466.70 ± 66.70 and 616.70 ± 87.20 on day 0, 7, 14, 21 and 28, respectively. The findings of the current study indicated that, the highest efficacy (62.26%) was recorded on day 14, whereas reduced efficacy of 47.10 and 30.18% was recorded on day 21 and 24, respectively.

QIAstat-Dx gastrointestinal panel and Luminex xTAG gastrointestinal pathogen panel comparative evaluation.

The diagnosis of acute gastroenteritis is an ongoing clinical challenge in terms of identification of the etiologic agent, time to results, and appropriate treatment. Rapid detection of gastrointestinal pathogens is needed to improve patient care. This study evaluates the performance of the QIAstat-Dx gastrointestinal panel (Q-GP; Investigational Use Only) compared to the Luminex xTAG gastrointestinal pathogen panel (L-GPP; US-IVD). Using 245 stool specimens, we evaluated 10 different targets including rotavirus, norovirus, Salmonella, Shigella, Campylobacter, Giardia, Cryptosporidium, Escherichia coli O157, enterotoxigenic E. coli (ETEC), and Shiga toxin-producing E. coli (STEC). For the viral targets, the percent positive agreement (PPA) for rotavirus was 100% (n = 19) and that for norovirus was 91% (20/22). For the parasitic targets, the PPA was 100% for Giardia and Cryptosporidium (n = 18 and n = 23, respectively). The PPA was 96% for Salmonella (22/23) and Campylobacter (22/23), and the PPA for Shigella was 100% (n = 23). For the E. coli targets, a PPA of 94% was achieved for STEC (32/34) and 96% for ETEC (24/25). We did not assess PPA for the E. coli O157 target as the Q-GP O157 call is stx dependent. The negative percent agreement across all targets was 99.1%. Our study suggests that QIAstat-Dx GP provides comparable results to Luminex GPP based on the analysis of targets found on both panels.

Identification and dynamics of novel scaffolds against Enterococcus faecium serine hydroxymethyltransferase enzyme: a potential target for antibiotics development

Serine hydroxymethyltransferase enzyme is a significant player in purine, thymidylate, and L-serine biosynthesis and has been tagged as a potential target for cancer, viruses, and parasites. However, this enzyme as an anti-bacterial druggable target has not been explored much. Herein, in this work, different computational chemistry and biophysics techniques were applied to identify potential computational predicted inhibitory molecules against Enterococcus faecium serine hydroxymethyltransferase enzyme. By structure based virtual screening process of ASINEX antibacterial library against the enzyme two main compounds: Top-1_BDC_21204033 and Top-2_BDC_20700155 were reported as best binding molecules. The Top-1_BDC_21204033 and Top-2_BDC_20700155 binding energy value is −9.3 and −8.9 kcal/mol, respectively. The control molecule binding energy score is −6.55 kcal/mol. The mean RMSD of Top-1-BDC_21204033, Top-2-BDC_20700155 and control is 3.7 Å (maximum 5.03 Å), 1.7 Å (maximum 3.05 Å), and 3.84 Å (maximum of 6.7 Å), respectively. During the simulation time, the intermolecular docked conformation and interactions were seen stable despite of few small jumps by the compounds/control, responsible for high RMSD in some frames. The MM/GBSA and MM/PBSA binding free energy of lead Top-2-BDC_20700155 complex is −79.52 and −82.63 kcal/mol, respectively. This complex was seen as the most stable compared to the control. Furthermore, the lead molecules and control showed good druglikeness and pharmacokinetics profile. The lead molecules were non-toxic and non-mutagenic. In short, the compounds are promising in terms of binding to the serine hydroxymethyltransferase enzyme and need to be subjected to experimental studies. Communicated by Ramaswamy H. Sarma